NASDAQ:DYN
Dyne Therapeutics, Inc. Stock News
$27.68
-1.07 (-3.72%)
At Close: May 17, 2024
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
10:33am, Wednesday, 18'th Jan 2023
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
All You Need to Know About Dyne Therapeutics, Inc. (DYN) Rating Upgrade to Strong Buy
01:32pm, Tuesday, 10'th Jan 2023
Dyne Therapeutics, Inc. (DYN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
07:30am, Tuesday, 03'rd Jan 2023
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop
Here's Why Dyne Therapeutics, Inc. (DYN) Is a Great 'Buy the Bottom' Stock Now
11:17am, Friday, 09'th Dec 2022
Dyne Therapeutics, Inc. (DYN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreeme
Dyne Therapeutics to Present at Investor Conferences in November
07:30am, Wednesday, 02'nd Nov 2022
WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop
Dyne Therapeutics to Present at Chardan's 6th Annual Genetic Medicines Conference
07:30am, Tuesday, 27'th Sep 2022
WALTHAM, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peo
Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
04:30pm, Tuesday, 06'th Sep 2022
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peo
Chardan Initiates Coverage On These 'Intriguing Small-Cap Stories"
04:07pm, Wednesday, 20'th Jul 2022
Chardan Research initiated coverage on Avidity Biosciences Inc (NASDAQ: RNA) with a Buy rating and a price target of $29 and Dyne Therapeutics Inc (NASDAQ: DYN) with a Buy rating and a price t
What's Going On With Dyne Therapeutics Shares Today?
10:24am, Tuesday, 05'th Jul 2022
Dyne Therapeutics Inc (NASDAQ: DYN) shares are trading lower by 5.42% to $6.81 after the company announced FDA clearance of its Investigational New Drug application for DYNE-251 for the treatment of
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
07:30am, Friday, 03'rd Jun 2022
WALTHAM, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with
Why Shares of Dyne Therapeutics Dropped 18.1% on Tuesday
04:18pm, Tuesday, 18'th Jan 2022
A clinical hold regarding one of the company's therapies brought Dyne's shares to a 52-week low.
Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
07:30am, Wednesday, 05'th Jan 2022
WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with
Dyne Therapeutics (DYN) Submits IND to FDA for DMD Candidate
04:48pm, Friday, 03'rd Dec 2021
Dyne Therapeutics (DYN) files an investigational new drug application in the United States for a clinical study on its investigational candidate DYNE-251 to address Duchenne Muscular Dystrophy.
Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day
07:45am, Wednesday, 13'th Oct 2021
- Investigational New Drug (IND) Submissions Anticipated for DYNE-251 in DMD During the Fourth Quarter of 2021 and for DYNE-101 in DM1 During the First Quarter of 2022 -
Dyne Therapeutics Highlights New Preclinical Data For Duchenne Muscular Dystrophy Program
10:21am, Friday, 01'st Oct 2021
Dyne Therapeutics Inc (NASDAQ: DYN) has announced new data presented today during the 2021 Muscle Study Group Annual Scientific Meeting for its Duchenne muscular dystrophy (DMD) program. DMD is a r
